ATE492549T1 - Polymorphe formen von n-(2,3-dimethyl-5,6,7,8- tetrahydrofuro(2,3-b)quinolin-4-yl)-2-(2- oxopyrrolidin-1 -yl)acetamid - Google Patents

Polymorphe formen von n-(2,3-dimethyl-5,6,7,8- tetrahydrofuro(2,3-b)quinolin-4-yl)-2-(2- oxopyrrolidin-1 -yl)acetamid

Info

Publication number
ATE492549T1
ATE492549T1 AT02720521T AT02720521T ATE492549T1 AT E492549 T1 ATE492549 T1 AT E492549T1 AT 02720521 T AT02720521 T AT 02720521T AT 02720521 T AT02720521 T AT 02720521T AT E492549 T1 ATE492549 T1 AT E492549T1
Authority
AT
Austria
Prior art keywords
tetrahydrofuro
oxopyrrolidin
acetamide
dimethyl
quinoline
Prior art date
Application number
AT02720521T
Other languages
English (en)
Inventor
Haruko Yamabe
Takayuki Ishige
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of ATE492549T1 publication Critical patent/ATE492549T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02720521T 2001-04-19 2002-04-19 Polymorphe formen von n-(2,3-dimethyl-5,6,7,8- tetrahydrofuro(2,3-b)quinolin-4-yl)-2-(2- oxopyrrolidin-1 -yl)acetamid ATE492549T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001121682 2001-04-19
JP2001121681 2001-04-19
PCT/JP2002/003916 WO2002085910A1 (en) 2001-04-19 2002-04-19 Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2- oxopyrrolidin -1 -yl)acetamide

Publications (1)

Publication Number Publication Date
ATE492549T1 true ATE492549T1 (de) 2011-01-15

Family

ID=26613875

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02720521T ATE492549T1 (de) 2001-04-19 2002-04-19 Polymorphe formen von n-(2,3-dimethyl-5,6,7,8- tetrahydrofuro(2,3-b)quinolin-4-yl)-2-(2- oxopyrrolidin-1 -yl)acetamid

Country Status (11)

Country Link
US (1) US6884805B2 (de)
EP (1) EP1392696B1 (de)
JP (1) JP2004525985A (de)
KR (1) KR100909923B1 (de)
CN (1) CN100484939C (de)
AT (1) ATE492549T1 (de)
CA (1) CA2439117C (de)
DE (1) DE60238674D1 (de)
HK (1) HK1061564A1 (de)
TW (1) TWI332503B (de)
WO (1) WO2002085910A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063201A1 (ja) * 2003-01-08 2004-07-29 Mitsubishi Pharma Corporation 統合失調症治療剤
RU2451512C2 (ru) * 2006-02-07 2012-05-27 Мицубиси Танабе Фарма Корпорейшн Нейрогенез, опосредованный производным 4-ациламинориридина
EP2068872A1 (de) 2006-09-08 2009-06-17 Braincells, Inc. Kombinationen mit einem 4-acylaminopyridin-derivat

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2029497C (en) 1989-11-08 2002-06-04 Kunihiro Ninomiya (Deceased) 4-acylaminopyridine derivative

Also Published As

Publication number Publication date
HK1061564A1 (en) 2004-09-24
CN100484939C (zh) 2009-05-06
KR20030097833A (ko) 2003-12-31
TWI332503B (en) 2010-11-01
KR100909923B1 (ko) 2009-07-29
CA2439117A1 (en) 2002-10-31
CN1498219A (zh) 2004-05-19
US6884805B2 (en) 2005-04-26
DE60238674D1 (de) 2011-02-03
EP1392696B1 (de) 2010-12-22
EP1392696A1 (de) 2004-03-03
US20040122034A1 (en) 2004-06-24
CA2439117C (en) 2011-02-08
JP2004525985A (ja) 2004-08-26
WO2002085910A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
HUP0400240A2 (hu) Szubsztituált oxazolidinonszármazékok és más hatóanyagok kombinációi és ezeket tartalmazó gyógyszerkészítmények
BR1100086A (pt) Derivados de fluoralcóxibenzilamino de heterocìclos contendo nitrogênio
FI935529A (fi) Aminometylensubstituerade icke-aromatiska heterocykliska foereningar
DK0772603T3 (da) Substituerede pyrimidinforbindelser og deres anvendelse
NO20025450D0 (no) Ny farmasöytisk sammensetning
ES2071334T3 (es) Analogos de anillos fusionados de nitrogeno conteniendo heterociclos no aromaticos.
TR200101859T2 (tr) Kemokin alıcı aktivitesinin modülatörleri olarak N-üreidoalkil-piperidinler
ATE383339T1 (de) Amin-derivate zur behandlung von apoptosis
NO941884L (no) 1,3-substituerte cykloalkener og cykloalkaner som sentralnervesystem-midler
FI940229A0 (fi) Trisykliset kondensoituneet heterosykliset yhdisteet, niiden valmistus ja käyttö
NO971625L (no) Nye peptider med immunomodulatoriske effekter
ATE313539T1 (de) Chinolin-4-carboxamidderivate als nk-3 und nk-2 rezeptor antagonisten
BR9609847A (pt) Derivados de N-(4-Benzila-substituída)-2-aminolactam
DE69530988D1 (de) Benzimidazolderivate mit dopaminerger wirkung
ATE492549T1 (de) Polymorphe formen von n-(2,3-dimethyl-5,6,7,8- tetrahydrofuro(2,3-b)quinolin-4-yl)-2-(2- oxopyrrolidin-1 -yl)acetamid
ES2103440T3 (es) Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen.
HUP0301594A2 (hu) E-metanikotin diacilborkősav sóját tartalmazó gyógyászati készítmények és alkalmazásuk a központi idegrendszer rendellenességeinek kezelésére
DE69030665D1 (de) (1,2n) und (3,2n)-karbozyklische-2-amino-tetralinderivate
NO934758D0 (no) Alkylsubstituerte heterosykliske forbindelser
ATE109139T1 (de) Mittel zum schutz von pflanzen gegen krankheiten.
PT703232E (pt) Derivados do 2,3-di-hidro-1h-isoindole processo para a sua preparacao e o seu uso como inibidores da reassimilacao da serotonina
NO20021950D0 (no) Fremgangsmåte for fremstilling av N-(4,5-bis-metansulfonyl-2- metylbenzoyl)-guanidin-hydroklorid
HUP0400776A2 (hu) N-(Metiletilaminokarbonil)-4-(3-metilfenilamino)-3-piridilszulfonamid és gyűrűs oligoszacharidok kompozíciói, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
TR200402685T4 (tr) Merkezi sinir sistemi üzerine etki eden siklobüta-indol karboksamid türevleri, bunların hazırlanma yöntemleri ve bunları içeren farmasötik bileşimler.
TR200101476T2 (tr) N-ikameli azabisikloaklan türevlerinin merkezi sinir sistemi bozukluklarının tedavisinde kullanılması

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties